Form 4: Calidi Biotherapeutics CEO Allan Camaisa Granted 40,000 Stock Options

Calidi Biotherapeutics CEO Allan Camaisa was granted 40,000 incentive stock options on June 17, 2024, under the company's 2023 Equity Incentive Plan.

Summary

• On June 17, 2024, Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics, Inc., was granted 40,000 incentive stock options.
• The options were granted under the company's 2023 Equity Incentive Plan.
• The exercise price is $0.215 per share, which is 110% of the closing price of Calidi's common stock on the grant date.
• The options vest in 1/48th installments monthly, commencing on January 1, 2024.
• The options expire on June 17, 2029.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The granting of stock options aligns the CEO's interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The size and terms of the grant are typical for executive compensation packages in similarly sized companies.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their leadership teams.
• The vesting schedule of 1/48th monthly is also a common practice, aligning with industry norms for retaining key personnel.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO to drive company performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates